Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial

Documenti analoghi

• CDP571, a humanised monoclonal antibody to tumour necrosis factor α, for moderate to severe Crohn’s disease: a randomised, double blind, placebo controlled trial
  di: Sandborn, W J, et al.
  Pubblicazione: (2004)
• Fontolizumab, a humanised anti‐interferon γ antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease
  di: Hommes, D W, et al.
  Pubblicazione: (2006)
• A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti‐interferon γ antibody, in patients with moderate to severe Crohn's disease
  di: Reinisch, W, et al.
  Pubblicazione: (2006)
• A phase II study of laquinimod in Crohn's disease
  di: D'Haens, Geert, et al.
  Pubblicazione: (2015)
• Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry
  di: Lichtenstein, Gary R, et al.
  Pubblicazione: (2012)